Previous Close | 0.1800 |
Open | 0.1900 |
Bid | 0.0000 x 1100 |
Ask | 0.0000 x 1000 |
Day's Range | 0.1750 - 0.2400 |
52 Week Range | 0.1100 - 13.3800 |
Volume | |
Avg. Volume | 288,580 |
Market Cap | 851,420 |
Beta (5Y Monthly) | 1.33 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -28.7780 |
Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for CALA
The Peninsula company's plan to close by the end of the first quarter is atypical in a biotech industry where executives try to keep their companies alive to the next milestone in order to raise more money.
Calithera Biosciences Inc (NASDAQ: CALA) announced that its Board of Directors has determined that it is in the best interests of its shareholders to dissolve the company and liquidate its assets. To reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter. The company intends to call its shareholders for a special meeting in the
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company’s operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all